LYMFKLIERKANKER. Non-Hodgkinlymfomen en ziekte van Hodgkin

Informatie over actuele ontwikkelingen in zowel reguliere als alternatieve en/of aanvullende behandelingen en middelen bij lymfklierkanker - non-Hodgkin lymfomen en ziekte van Hodgkin in alle stadia.

In linkerkolom staan recente artikelen min of meer op alfabetische volgorde gerubriceerd

Ervaringen van kankerpatienten met complementaire aanpak zijn te vinden onder ervaringsverhalen en er zijn op onze website ook een aantal video's van ervaringen van kankerpatienten met complementaire aanpak te zien. Aan te klikken via videoknop linksbovenaan op deze pagina. Of ga naar de website van het SNFK waar voorlichtingsfilmpjes zijn te zien over complementaire aanpak bij kanker.

Als u ons wilt ondersteunen dan kan dat via een donatie: zie inschrijving OPS

Brentuximab Vedotin (SGN-35) blijkt succesvolle aanpak voor gevorderde en recidief van lymfklierkanker, non-hodgkin lymfomen met CD30 positieve expressie. Volgens de Volkskrant is er een run op dit medicijn ontstaan, waardoor er een tekort is. Artikel geplaatst 7 juni 2011

Brentuximab Vedotin (SGN-35) blijkt een zo succesvolle aanpak van non-Hodgkin lymfomen dat er een tekort aan het ontstaan is aan dit medicijn. Zo meldt de Volkskrant  vandaag in een pagina groot artikel. Ik heb de studie er eens bijgehaald die recent nog is gepubliceerd in het NEJM (New England Journal of Medicin) en de resultaten lijken inderdaad veelbelovend. Maar het is nog slechts een fase I/II studie en is nogal prematuur om dit zo pontificaal te presenteren ljikt mij. Op de website van Seattle Genetics  staat meer over lopende studies met dit middel.

Hier het abstract van de studie. Als u het volledige studierapport wilt lezen klik hier, het is vrij te lezen.

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Anas Younes, M.D., Nancy L. Bartlett, M.D., John P. Leonard, M.D., Dana A. Kennedy, Pharm.D., Carmel M. Lynch, Ph.D., Eric L. Sievers, M.D., and Andres Forero-Torres, M.D.

N Engl J Med 2010; 363:1812-1821November 4, 2010

Background

Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous attempts to target the CD30 antigen with monoclonal-based therapies have shown minimal activity. To enhance the antitumor activity of CD30-directed therapy, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific monoclonal antibody by an enzyme-cleavable linker, producing the antibody–drug conjugate brentuximab vedotin (SGN-35).

Methods

In this phase 1, open-label, multicenter dose-escalation study, we administered brentuximab vedotin (at a dose of 0.1 to 3.6 mg per kilogram of body weight) every 3 weeks to 45 patients with relapsed or refractory CD30-positive hematologic cancers, primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma. Patients had received a median of three previous chemotherapy regimens (range, one to seven), and 73% had undergone autologous stem-cell transplantation.

Results

The maximum tolerated dose was 1.8 mg per kilogram, administered every 3 weeks. Objective responses, including 11 complete remissions, were observed in 17 patients. Of 12 patients who received the 1.8-mg-per-kilogram dose, 6 (50%) had an objective response. The median duration of response was at least 9.7 months. Tumor regression was observed in 36 of 42 patients who could be evaluated (86%). The most common adverse events were fatigue, pyrexia, diarrhea, nausea, neutropenia, and peripheral neuropathy.

Conclusions

Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study. Treatment was associated primarily with grade 1 or 2 (mild-to-moderate) toxic effects. (Funded by Seattle Genetics; ClinicalTrials.gov number, NCT00430846.)

References

  1. 1

    Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395[Erratum, N Engl J Med 2005;353:744.]
    Full Text | Web of Science | Medline

  2. 2

    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249
    CrossRef | Web of Science | Medline

  3. 3

    Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16:625-633
    CrossRef | Web of Science | Medline

  4. 4

    Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006;12:1065-1072
    CrossRef | Web of Science | Medline

  5. 5

    Martinez C, Canals C, Alessandrino E, et al. Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): prognostic factors in 462 patients registered in the database of the EBMT. J Clin Oncol 2010;28:Suppl:7s-7s
    CrossRef

  6. 6

    Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009:507-19.

  7. 7

    Stein H, Delsol G, Pileri SA, Weiss LM, Poppema S, Jaffe ES. Classical Hodgkin lymphoma: introduction. In Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer, 2008:326-29.

  8. 8

    van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells: a possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999;154:1685-1691
    CrossRef | Web of Science | Medline

  9. 9

    Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005;105:4553-4560
    CrossRef | Web of Science | Medline

  10. 10

    Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992;68:421-427
    CrossRef | Web of Science | Medline

  11. 11

    Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1-14
    Web of Science | Medline

  12. 12

    Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol 2004;172:2186-2193
    Web of Science | Medline

  13. 13

    Tian ZG, Longo DL, Funakoshi S, et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res 1995;55:5335-5341
    Web of Science | Medline

  14. 14

    Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-2769
    CrossRef | Web of Science | Medline

  15. 15

    Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-179
    CrossRef | Web of Science | Medline

  16. 16

    Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-784
    CrossRef | Web of Science | Medline

  17. 17

    Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10:7063-7070
    CrossRef | Web of Science | Medline

  18. 18

    Sun MM, Beam KS, Cerveny CG, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 2005;16:1282-1290
    CrossRef | Web of Science | Medline

  19. 19

    McDonagh CF, Turcott E, Westendorf L, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 2006;19:299-307
    CrossRef | Web of Science | Medline

  20. 20

    Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber H-P. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008;142:69-73
    CrossRef | Web of Science | Medline

  21. 21

    Weihrauch MR, Manzke O, Beyer M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 2005;65:5516-5519
    CrossRef | Web of Science | Medline

  22. 22

    Niens M, Visser L, Nolte IM, et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 2008;140:527-536
    CrossRef | Web of Science | Medline

  23. 23

    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655
    CrossRef | Web of Science | Medline

  24. 24

    Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: Cancer Therapy Evaluation Program, 2006. (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.)

  25. 25

    Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586
    CrossRef | Web of Science | Medline

  26. 26

    Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 1998;16:584-588
    Web of Science | Medline

  27. 27

    Rule S, Tighe M, Davies S, Johnson S. Vinorelbine in the treatment of lymphoma. Hematol Oncol 1998;16:101-105
    CrossRef | Web of Science | Medline

  28. 28

    Zinzani PL, Bendandi M, Stefoni V, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000;85:926-929
    Medline

  29. 29

    Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004;5:110-115
    CrossRef | Medline

  30. 30

    Aurer I, Radman I, Nemet D, et al. Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease. Onkologie 2005;28:567-571
    CrossRef | Web of Science | Medline

  31. 31

    Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008;112:831-836
    CrossRef | Web of Science | Medline

  32. 32

    Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-1079
    CrossRef | Web of Science | Medline

  33. 33

    Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24:1633-1642
    CrossRef | Web of Science | Medline

  34. 34

    Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008;6:455-467
    Medline